Piramal Pharma Ltd Upgraded to Hold by MarketsMOJO on Technical Improvements

Technical Trends Shift to Mildly Bullish

The primary catalyst for the rating upgrade stems from a marked improvement in the technical outlook. The technical grade has shifted from mildly bearish to mildly bullish, driven by a combination of weekly and daily indicators. The Moving Average Convergence Divergence (MACD) on a weekly basis is bullish, while the monthly MACD remains mildly bearish, indicating some longer-term caution.

Other technical signals include a mildly bullish stance from Bollinger Bands on the weekly chart, supported by a bullish daily moving average. The Know Sure Thing (KST) indicator is bullish weekly but bearish monthly, reflecting mixed momentum across timeframes. Meanwhile, the On-Balance Volume (OBV) shows no clear weekly trend but is bullish monthly, suggesting accumulation by investors over the longer term.

Overall, these technical signals have improved the stock’s momentum, encouraging a more positive outlook from market analysts and contributing significantly to the upgrade.

Valuation Remains Fair with Discount to Peers

From a valuation perspective, Piramal Pharma is considered fairly valued with an Enterprise Value to Capital Employed (EV/CE) ratio of 2.2, which is modest compared to industry peers. The company’s Return on Capital Employed (ROCE) stands at 0.7%, indicating limited efficiency in generating returns from capital but still within a reasonable range for a small-cap pharmaceutical firm.

The stock currently trades at ₹174.75, up from the previous close of ₹171.75, and remains below its 52-week high of ₹220.90. This pricing reflects a discount relative to historical valuations of its sector, offering potential upside if operational improvements materialise. However, the relatively low ROCE and subdued profitability metrics temper enthusiasm, justifying a Hold rating rather than a Buy.

Financial Trend: Mixed Signals Amid Flat Quarterly Performance

Financially, Piramal Pharma’s recent quarterly results for Q4 FY25-26 were largely flat, with no significant growth in revenues or profits. The company’s operating profit has grown at an annualised rate of 56.94% over the longer term, signalling healthy underlying growth potential. However, this is contrasted by a sharp decline in profitability over the past year, with profits falling by 242.4% and the stock delivering a negative return of -18.61% over the same period.

Net sales have grown at a modest annual rate of 7.79% over the last five years, indicating slow but steady top-line expansion. Return on Equity (ROE) remains low at an average of 0.58%, reflecting limited profitability per unit of shareholder funds. The company’s ability to service debt is a concern, with a high Debt to EBITDA ratio of 6.16 times and a debt-equity ratio of 0.70 times, the highest in recent half-year data. These factors weigh on the financial trend assessment, limiting the scope for a more optimistic rating.

Market Performance and Institutional Confidence

Despite underperforming the broader market in the last year, Piramal Pharma has outpaced the Sensex over longer horizons. The stock has delivered a 93.28% return over three years, significantly outperforming the Sensex’s 16.84% gain. Year-to-date, the stock has risen 1.42%, while the Sensex has declined by 9.43%, indicating some recent resilience.

Institutional investors hold a substantial 45.79% stake in the company, signalling confidence from well-resourced market participants who typically conduct rigorous fundamental analysis. This institutional backing provides a degree of stability and suggests that the stock’s current valuation and technical improvements are being recognised by knowledgeable investors.

Technical and Fundamental Balance Justifies Hold Rating

The upgrade from Sell to Hold reflects a balanced view of Piramal Pharma’s prospects. Improved technical indicators suggest a mild bullish momentum that could support price appreciation in the near term. Valuation metrics indicate the stock is reasonably priced relative to peers, offering some margin of safety for investors.

However, the company’s financial challenges, including weak profitability, high leverage, and flat recent results, constrain the outlook. The stock’s underperformance over the past year relative to the market and its peers further tempers enthusiasm. Consequently, the Hold rating is appropriate, signalling cautious optimism while awaiting clearer signs of sustained operational improvement.

Outlook and Investor Considerations

Investors should monitor Piramal Pharma’s upcoming quarterly results and debt servicing metrics closely. Any signs of improved profitability or deleveraging could prompt a further upgrade. Conversely, continued flat performance or worsening leverage would likely maintain or worsen the rating.

Given the company’s small-cap status and sector dynamics, volatility is expected. Institutional ownership provides some confidence, but retail investors should weigh the risks carefully. The stock’s recent price action and technical signals offer a tactical entry point for those with a medium-term horizon and tolerance for risk.

Summary of Key Metrics

Current Price: ₹174.75 (up 1.75% on the day)
52-Week Range: ₹132.50 - ₹220.90
Market Cap Grade: Small-cap
Mojo Score: 55.0 (Hold, upgraded from Sell)
Debt to EBITDA: 6.16 times
Debt-Equity Ratio: 0.70 times
ROCE: 0.7%
Operating Profit Growth (Annualised): 56.94%
Net Sales Growth (5 years annualised): 7.79%
Institutional Holdings: 45.79%

Comparative Returns

1 Week: +1.66% vs Sensex +0.58%
1 Month: +6.72% vs Sensex +0.49%
Year-to-Date: +1.42% vs Sensex -9.43%
1 Year: -18.61% vs Sensex -6.59%
3 Years: +93.28% vs Sensex +16.84%

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →